Binge-Eating Disorder - Pipeline Insight, 2025

This “Binge-Eating Disorder - Pipeline Insight, 2025” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Binge-Eating Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Binge-Eating Disorder: Understanding

Binge-Eating Disorder: Overview

Binge eating disorder (BED) is a mental illness characterized by regular episodes of binge eating. Binge eating involves eating an excessive amount of food, which may take place in a rapid space of time, or may be more of an extended grazing. These episodes can feel chaotic, uncontrollable and highly distressing. During a binge eating episode, a person may not be hungry, but may continue to eat past the point of feeling comfortably full. It is common for people to binge eat alone or in secret, and experience intense feelings of guilt, shame, disgust and low mood after a binge. A binge is different from overeating and is far more pervasive. It is the intense drive to overeat which is experienced again and again over time, accompanied by feelings of shame, guilt and feeling out of control.

Diagnosing BED involves a thorough evaluation by a healthcare provider, including a physical exam, psychological assessment, and discussion of eating habits and behaviors. It is essential to differentiate BED from occasional overeating or emotional eating to provide appropriate treatment.

Treatment for BED typically involves a combination of psychotherapy, such as cognitive-behavioral therapy (CBT) or interpersonal therapy, to address the underlying emotional issues and develop healthier coping mechanisms. Additionally, medication may be prescribed in some cases to manage symptoms like depression or anxiety that often coexist with BED. Self-care strategies play a crucial role in managing BED. These may include maintaining regular eating patterns, avoiding restrictive diets, practicing mindfulness and stress-reduction techniques, and engaging in regular physical activity. Support from family and friends, as well as participation in support groups or counseling, can also be beneficial for individuals struggling with BED.

'Binge-Eating Disorder- Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Binge-Eating Disorder pipeline landscape is provided which includes the disease overview and Binge-Eating Disorder treatment guidelines. The assessment part of the report embraces, in depth Binge-Eating Disorder commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Binge-Eating Disorder collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Binge-Eating Disorder R&D. The therapies under development are focused on novel approaches to treat/improve Binge-Eating Disorder.

Binge-Eating Disorder Emerging Drugs Chapters

This segment of the Binge-Eating Disorder report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Binge-Eating Disorder Emerging Drugs

Solriamfetol: Axsome Therapeutics, Inc.

It is a medication developed by Axsome Therapeutics, Inc. It is primarily indicated for the treatment of excessive daytime sleepiness (EDS) associated with narcolepsy and obstructive sleep apnea (OSA). Solriamfetol functions as a dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI), which helps improve wakefulness in adults suffering from these conditions. The drug is currently in Phase III stage of its clinical trial evaluation for the treatment of Binge-Eating Disorder.

Binge-Eating Disorder: Therapeutic Assessment

This segment of the report provides insights about the different Binge-Eating Disorder drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Binge-Eating Disorder

• There are approx. 3+ key companies which are developing the therapies for Binge-Eating Disorder. The companies which have their Binge-Eating Disorder drug candidates in the most advanced stage, i.e. Phase III include, Axsome Therapeutics, Inc.

Phases

The report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Binge-Eating Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Binge-Eating Disorder: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Binge-Eating Disorder therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Binge-Eating Disorder drugs.

Binge-Eating Disorder Report Insights

• Binge-Eating Disorder Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Binge-Eating Disorder Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Binge-Eating Disorder drugs?
• How many Binge-Eating Disorder drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Binge-Eating Disorder?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Binge-Eating Disorder therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Binge-Eating Disorder and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• TRYP Therapeutics
• Axsome Therapeutics, Inc.

Key Products

• TRYP-8803
• Solriamfetol

This product will be delivered within 2 business days.